Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Dermatoscopic findings of granulomatous diseases
Cutaneous sarcoidosis, necrobiosis lipoidica and granuloma anulare
- Clostridioides difficile infection: specific therapy
Importance of vancomycin and fidaxomicin has increased
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP
Differentiate chronic inflammatory demyelinating polyneuropathy (CIDP)
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity
Prospect of improved cardiovascular prognosis
- Case report: alveolar sarcoidosis
Acute hypoxemic respiratory failure as initial manifestation
- "Swiss Health Care Atlas"